David A. Wohl

机构：University of North Carolina at Chapel Hill · ORCID：0000-0002-7764-0212

发表论文 475 篇 · 总被引 12107 次 · h-index 57

代表论文

• Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial (2025 · Clinical Infectious Diseases · 被引 17)
• Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data (2025 · JAMA Network Open · 被引 6)
• Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357 (2025 · Clinical Infectious Diseases · 被引 5)
• Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme (‘ENABLE 1.5’) – study protocol (2025 · BMJ Public Health · 被引 3)
• Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia (2026 · The Lancet Infectious Diseases · 被引 2)
• Health-economic impacts of age-targeted and sex-targeted Lassa fever vaccination in endemic regions of Nigeria, Guinea, Liberia, and Sierra Leone: a modelling study (2026 · The Lancet Global Health · 被引 2)